Başkan, Emel Bülbül2024-09-102024-09-102022-01-012717-6398https://doi.org/10.4274/turkderm.galenos.2022.06978https://hdl.handle.net/11452/44503https://jag.journalagent.com/turkderm/pdfs/TURKDERM_56_50_75_76.pdfFor a drug to be defined as a biosimilar, it should be fairly similar to the previously approved original or reference product. The minor variances in its inactive ingredients should not pose clinically significant differences from the reference product in terms of safety and efficacy potency. Biosimilars of infliximab and adalimumab have received reimbursements in our country. By lowering treatment costs, biosimilars may provide considerable economies for health systems that reimburse healthcare expenditures.enPsoriasisBiosimilarsBiologicsScience & technologyLife sciences & biomedicineDermatologyArticle00084012380002075765610.4274/turkderm.galenos.2022.06978